封面
市场调查报告书
商品编码
1178054

NAMPT抑制剂市场 - 开发平台分析 - 全球产业分析,规模,占有率,成长,趋势,预测(2022年~2031年)

NAMPT Inhibitors Pipeline Analysis (Phase: Phase II, Phase I/II, Phase I, and Preclinical; and Type of Molecule: Small Molecules and Biologics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

出版日期: | 出版商: Transparency Market Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

本报告提供全球NAMPT抑制剂市场相关调查,提供市场概要,以及2022年~2031年的预测,各相,各用途,各分子类型,各地区的趋势,及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 前提与调查手法

第3章 摘要整理:全球NAMPT抑制剂市场

第4章 市场概要

  • 简介
  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会

第5章 主要洞察

第6章 北美的NAMPT抑制剂市场分析与预测

  • 简介
    • 主要调查结果
  • 市场分析,各相,2017年~2031年
    • 第二阶段
    • 第一/二阶段
    • 第一阶段
    • 前临床
  • 市场分析,各用途,2017年~2031年
    • 肿瘤学
    • 其他(呼吸系统·神经疾病)
  • 市场分析,各分子类型,2017年~2031年
    • 低分子
    • 生技药品

第7章 欧洲的NAMPT抑制剂市场分析与预测

第8章 其他地区的NAMPT抑制剂市场分析与预测

第9章 竞争情形

  • 市场参与企业-竞争矩阵(各等级及各企业规模)
  • 企业简介
    • Onxeo
    • Aqualung Therapeutics
    • Antengene Corporation
    • OncoTartis, Inc.
    • Karyopharm Therapeutics
简介目录
Product Code: TMRGL85238

TMR's report on the global NAMPT inhibitors pipeline analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global NAMPT inhibitors pipeline analysis market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global NAMPT inhibitors pipeline analysis market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the NAMPT inhibitors pipeline analysis market.

The report delves into the competitive landscape of the global NAMPT inhibitors pipeline analysis market. Key players operating in the global NAMPT inhibitors pipeline analysis market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global NAMPT inhibitors pipeline analysis market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global NAMPT Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Phase Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities

5. Key Insights

  • 5.1. Overview on Kay players operating in the market space
  • 5.2. Key industry events (mergers, acquisitions, partnerships, etc.)
  • 5.3. COVID-19 pandemic impact on industry

6. North America NAMPT Inhibitors Market Analysis and Forecast

  • 6.1. Introduction
    • 6.1.1. Key Findings
  • 6.2. Market Analysis, by Phase, 2017 - 2031
    • 6.2.1. Phase II
    • 6.2.2. Phase I/II
    • 6.2.3. Phase I
    • 6.2.4. Preclinical
  • 6.3. Market Analysis, by Application, 2017 - 2031
    • 6.3.1. Oncology
    • 6.3.2. Others (respiratory and neurology disorders)
  • 6.4. Market Analysis, by Type of Molecule, 2017 - 2031
    • 6.4.1. Small Molecules
    • 6.4.2. Biologics

7. Europe NAMPT Inhibitors Market Analysis and Forecast

  • 7.1. Introduction
    • 7.1.1. Key Findings
  • 7.2. Market Analysis, by Phase, 2017 - 2031
    • 7.2.1. Phase II
    • 7.2.2. Phase I/II
    • 7.2.3. Phase I
    • 7.2.4. Preclinical
  • 7.3. Market Analysis, by Application, 2017 - 2031
    • 7.3.1. Oncology
    • 7.3.2. Others (Respiratory and Neurology Disorders)
  • 7.4. Market Analysis, by Type of Molecule, 2017 - 2031
    • 7.4.1. Small Molecules
    • 7.4.2. Biologics

8. Rest of the World NAMPT Inhibitors Market Analysis and Forecast

  • 8.1. Introduction
    • 8.1.1. Key Findings
  • 8.2. Market Analysis, by Phase, 2017 - 2031
    • 8.2.1. Phase II
    • 8.2.2. Phase I/II
    • 8.2.3. Phase I
    • 8.2.4. Preclinical
  • 8.3. Market Analysis, by Application, 2017 - 2031
    • 8.3.1. Oncology
    • 8.3.2. Others (Respiratory and Neurology Disorders)
  • 8.4. Market Analysis, by Type of Molecule, 2017 - 2031
    • 8.4.1. Small Molecules
    • 8.4.2. Biologics

9. Competition Landscape

  • 9.1. Market Player - Competition Matrix (by tier and size of companies)
  • 9.2. Company Profiles
    • 9.2.1. Onxeo
      • 9.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 9.2.1.2. Product Portfolio
      • 9.2.1.3. SWOT Analysis
      • 9.2.1.4. Strategic Overview
    • 9.2.2. Aqualung Therapeutics
      • 9.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 9.2.2.2. Product Portfolio
      • 9.2.2.3. SWOT Analysis
      • 9.2.2.4. Strategic Overview
    • 9.2.3. Antengene Corporation
      • 9.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 9.2.3.2. Product Portfolio
      • 9.2.3.3. SWOT Analysis
      • 9.2.3.4. Strategic Overview
    • 9.2.4. OncoTartis, Inc.
      • 9.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 9.2.4.2. Product Portfolio
      • 9.2.4.3. SWOT Analysis
      • 9.2.4.4. Strategic Overview
    • 9.2.5. Karyopharm Therapeutics
      • 9.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 9.2.5.2. Product Portfolio
      • 9.2.5.3. SWOT Analysis
      • 9.2.5.4. Strategic Overview